This evidence, together with a recent genome-wide association study linking a locus containing PPARγ with improved survival in a rodent malaria model [19], led us to speculate that pharmacologically targeting the signalling pathways involved in PPARγ/CD36 expression during a malarial infection might improve CM treatment outcome. This evidence concerns the gene CD36 and malaria.